The Ebola virus (EBOV) and Marburg virus (MARV) have been in circulation in Africa for several decades and are the cause of numerous outbreaks. There has been very little research on the role of domestic animals in their transmission to humans, but studies have only been conducted in dogs and pigs where relatively high levels of IgG was detected. These levels suggest that ruminants, which have not been studied, should also be investigated. This study aims at evaluating the circulation of MARV and EBOV in dogs, sheep and goats and to assess their exposure to these two viruses. Between November 2018 and March 2023, a total of 448 domestic animal sera or plasma samples, including 128 dogs, 222 goats and 98 sheep, were analyzed by serological and molecular methods. The Luminex technique was employed for the detection of IgG antibodies against EBOV NP, GP, MARV GP and VP40, while EBOV specific and pan-filovirus polymerase chain reaction amplification was used for molecular analysis. All samples tested negative for EBOV and MARV RNA. However, our results showed that 2/128 (1.5%) dogs, 1/222 (0.4%) goats and 3/98 (3.1%) sheep displayed NP and GP anti-EBOV antibodies. In addition, 2/128 (1.5%) dogs displayed GP and VP40 anti-MARV antibodies, while no antibodies were detected in goats and sheep. Over all, these results suggest that dogs and small ruminants are naturally exposed to EBOV and MARV. In the absence of clinically sick individuals, the presence of IgG-positive animals suggests various sources of exposure, such as contaminated fruits with the urine and saliva of bats or dead bats fallen on the ground ate by dogs. These contaminated substrates are both consumed by both dogs and small ruminants. The findings provide new insights into the circulation and exposure of EBOV and MARV in domestic animals, emphasising their potential use as sentinels. Furthermore, they prompt significant considerations regarding the potential risk to humans in this region.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882094 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0314801 | PLOS |
PLoS One
March 2025
Département de Virologie, Centre Interdisciplinaire de Recherches Médicales de Franceville (CIRMF), Franceville, Gabon.
The Ebola virus (EBOV) and Marburg virus (MARV) have been in circulation in Africa for several decades and are the cause of numerous outbreaks. There has been very little research on the role of domestic animals in their transmission to humans, but studies have only been conducted in dogs and pigs where relatively high levels of IgG was detected. These levels suggest that ruminants, which have not been studied, should also be investigated.
View Article and Find Full Text PDFVaccines (Basel)
December 2024
IAVI, 125 Broad St, New York, NY 10004, USA.
: Orthoebolaviruses and orthomarburgviruses are filoviruses that can cause viral hemorrhagic fever and significant morbidity and mortality in humans. The evaluation and deployment of vaccines to prevent and control Ebola and Marburg outbreaks must be informed by an understanding of the transmission and natural history of the causative infections, but little is known about the burden of asymptomatic infection or undiagnosed disease. This systematic review of the published literature examined the seroprevalence of antibodies to orthoebolaviruses and orthomarburgviruses in sub-Saharan Africa.
View Article and Find Full Text PDFJ Med Chem
January 2025
UICentre: Drug Discovery, University of Illinois Chicago, Chicago, Illinois 60612, United States.
Ebola and Marburg (EBOV and MARV) filoviral infections lead to fatal hemorrhagic fevers and have caused over 30 outbreaks in the last 50 years. Currently, there are no FDA-approved small molecule therapeutics for effectively treating filoviral diseases. To address this unmet medical need, we have conducted a systematic structural optimization of an early lead compound, -(4-(4-methylpiperidin-1-yl)-3-(trifluoromethyl)phenyl)-4-(morpholinomethyl)benzamide (), borne from our previously reported hit-to-lead effort.
View Article and Find Full Text PDFMethods Mol Biol
November 2024
Department of Microbiology and Immunology, University of Iowa, Iowa City, IA, USA.
Methods Mol Biol
November 2024
Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
Vesicular stomatitis virus (VSV)-based vaccination has shown protective efficacy against filovirus infection. Following the approval of a VSV-based vaccine against Ebola virus, there have been efforts toward applying the same platform for other filoviruses, including Marburg virus (MARV) and Sudan virus. Because these vaccines express filovirus glycoproteins, they are also a valuable tool to study filovirus entry under biosafety level 2 conditions.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!